Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects

Atherosclerosis

Volumn 148, Issue 1, 2000, Pages 171-177

  Shoji, Tetsuo ^a   Nishizawa, Yoshiki ^a   Fukumoto, Mariko ^a   Shimamura, Kyoko ^b   Kimura, Junji ^b   Kanda, Hiroyuki ^a   Emoto, Masanori ^a   Kawagishi, Takahiko ^a   Morii, Hirotoshi ^a  

^a Osaka Prefecture University   (Japan)

^b Vessel Research Laboratory Inc   (Japan)

Author keywords

Anti oxidized LDL antibody titer; Cholesterol; Immunoglobulin; Oxidized LDL; Phosphatidylcholine

Indexed keywords

ANTIBODY; APOLIPOPROTEIN B; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ANTIBODY TITER; ARTICLE; ATHEROGENESIS; BLOOD ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; IMMUNIZATION; JAPAN; MALE; MULTIPLE REGRESSION; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; AGED; ANTIBODIES; APOLIPOPROTEINS B; CHOLESTEROL, LDL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PHOSPHATIDYLCHOLINES; REFERENCE VALUES; REGRESSION ANALYSIS;

EID: 0033990553     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00218-X     Document Type: Article

References (52)

1. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond cholesterol: modification of low density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320:1989;915-924.
2. Navab M., Berliner J.A., Watson A.D. et al. The Yin and Yang of oxidation in the development of the fatty streak. Arterioscler. Thromb. Vasc. Biol. 16:1996;831-842.
3. Steinbrecher U.P., Parthasarathy S., Leake D.S., Witzum J.L., Steinberg D. Proc. Natl. Acad. Sci. USA. 81:1984;3883-3887.
4. Itabe H., Takeshima E., Iwasaki H., Kimura J., Yoshida Y., Imanaka T., Takano T. A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. J. Biol. Chem. 269:1994;15274-15279.
5. Kodama T., Freeman M., Rohrer L., Zabrecky J., Matsudaira P., Krieger M. Type I macrophage scavenger receptor contains a-helical and collagen-like coiled coils. Nature. 343:1990;531-535.
6. Elomaa O., Kangas M., Sahlberg C., Tuukkanen J., Sormunen R., Liakka A., Thesleff I., Kraal G., Yryggvason K. Cloning of a novel bacteria-binding receptor structually related to scavenger receptors and expressed in a subset of macrophages. Cell. 80:1995;603-609.
7. Endemann G., Stanton L.W., Madden K.S., Bryant C.M., White R.T., Protter M.A. CD36 is a receptor for oxidized low density lipoprotein. J. Biol. Chem. 268:1993;11811-11816.
8. Acton S.L., Scherer P.E., Lodish H.F., Krieger M. Expression cloning of SR-BI, a CD36-related class B scavenger receptor. J. Biol. Chem. 269:1994;21003-21009.
9. Pearson A., Lix A., Krieger M. Expression cloning of SR-CI, a class C macrophage-specific scavenger receptor from Drosophia melanoggaster. Proc. Natl. Acad. Sci. USA. 92:1995;4056-5060.
10. Stanton L.W., White R.T., Bryant C.M., Protter A.A., Endemann G. A macrophage Fc receptor for IgG is also a receptor for oxidized low density lipoprotein. J. Biol. Chem. 267:1992;22446-22451.
11. Ramprasad M.P., Fisher W., Witztum J.L., Sambrano G.R., Quehenberger O., Steinberg D. The 94- to 97-kDa mouse macrophage membrane protein that recognizes oxidized low density lipoprotein and phosphatidylserine-rich liposomes is identical to macrosialin, the mouse homologue of human CD68. Proc. Natl. Acad. Sci. USA. 92:1995;9580-9584.
12. Clare K., Hardwick S., Carpenter K., Weerantunge N., Mitchinson M. Toxicity of oxysterols to human monocyte-macrophages. Atherosclerosis. 118:1995;67-75.
13. Kugiyama K., Kerns S., Morrisett J., Roberts R., Henry P. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified lipoproteins. Nature. 344:1990;160-162.
14. Lehr H., Hubner C., Nolte D., Finckh B., Beisiegel U., Kohlschutter A., Messmer K. Oxidatively modified human low-density lipoprotein stimulates leukocyte adherence to the microvascular endothelium in vivo. Res. Exp. Med. 191:1991;85-90.
15. Sakai M., Miyazaki A., Hakamata H., Sasaki T., Yui S., Yamazaki M., Shichiri M., Horiuchi S. Lysophosphatidylcholine plays an essential role in the motogenic effect of oxidized low density lipoprotein on murine macrophages. J. Biol. Chem. 269:1994;31430-31435.
16. Witztum J.L. Immunological response to oxidized LDL. Atherosclerosis. 131:1997;S9-S11.
17. Hansson G.K. Cell-mediated immunity in atherosclerosis. Curr. Opin. Lipidol. 8:1997;301-311.
18. Munro J.M., van der Walt J.D., Munro C.S., Chalmers J.A.C., Cox E.L.: An immunohistochemical analysis of human aortic fatty streaks. Hum. Pathol. 18:1987;375-380.
19. Zhou X., Stemme S., Hansson G.K. Evidence for a local immune response in atherosclerosis. CD4+ T cells infiltrate lesions of apoE-deficient mice. Am. J. Pathol. 149:1996;359.
20. Sohma Y., Sasano H., Shiga R., Saeki S., Suzuki T., Nagura H., Nose M., Yamamoto T. Accumulation of plasma cells in atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits. Proc. Natl. Acad. Sci. USA. 92:1995;4937-4941.
21. Yla-Herttuala S., Palinski W., Butler S.W., Picard S., Steinberg D., Witztum J.L. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler. Thromb. 14:1994;32-40.
22. Virella G., Virella I., Leman R.B., Pryor M.B., Lopes-Virella M.F. Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. Int. J. Clin. Lab. Res. 23:1993;95-101.
23. Bergmark C., Wu R., de Faire U., Lefvert A.K., Swedenborg J. Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler. Thromb. Vasc. Biol. 15:1995;441-445.
24. Maggi E., Chiesa R., Melissano G., Castellano R., Astore D., Grossi A., Finardi G., Bellomo G. LDL oxidation in patients with severe carotid atherosclerosis: a study in vitro and in vivo oxidation markers. Arterioscler. Thromb. 14:1994;1892-1899.
25. Salonen J.T., Yla-Herttula S., Yamamoto R., Butler S., Korpela H., Salonen R., Nyyssonen K., Palinski W., Witztum J.L. Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet. 339:1992;883-887.
26. Uusitupa M.I., Niskanen L., Luoma J., Vilja P., Mercuri M., Rauramaa R., Yla-Herttuala S. Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependnet diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 16:1996;1236-1242.
27. Cherubini A., Mecocci P., Senin U. Autoantibodies against oxidized low-density lipoproteins in older stroke patients. J. Am. Geriatr. Soc. 45:1997;125.
28. Schumacher M., Eber B., Tatzber F. et al. Transient reduction of atutoantibodies against oxidized LDL in patients with acute myocardial infarction. Free Radic. Biol. Med. 18:1995;1087-1091.
29. Ameli S., Hultgardh-Nilsson A., Regnstrom J., Calara F., Yano J., Cercek B., Shah P.K., Nilsson J. Effect of immunization with homologous LDL and oxidized LDL on eartly atherosclerosis in hypercholesterolemic rabbits. Arterioscler. Thromb. Vasc. Biol. 16:1996;1074-1079.
30. Palinski W., Miller E., Witztum J. Immunization of low density lipoprotein (LDL) receptor deficient rabbits with homologous malondialdehyde-modified LDL reduces atherosclerosis. Proc. Natl. Acad. Sci. USA. 92:1995;821-825.
31. Roselaar S.E., Schonfeld G., Daugherty A. Enhanced develpment of atherosclerosis in cholesterol-fed rabbits by suppression of cell-mediated immunity. J. Clin. Invest. 96:1995;1389-1394.
32. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 20:1997;1183-1197.
33. Bruce R.A. Exercise testing of patients with coronary artery disease. Ann. Clin. Res. 3:1971;323.
34. Itabe H., Yamamoto H., Imanaka T., Shimamura K., Uchiyama H., Kimura J., Sanaka T., Hata Y., Takano T. Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J. Lipid. Res. 37:1996;45-53.
35. Itabe H., Takeshima E., Iwasaki H., Kimura J., Yoshida Y., Imanaka T., Takano T. A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atheroclerotic lesions. J. Biol. Chem. 269:1994;15274-15279.
36. Itabe H., Yamamoto H., Suzuki M., Kawai Y., Nakagawa Y., Suzuki A., Imanaka T., Takano T. Oxidized phosphatidylcholines that modify proteins. Analysis by monoclonal antibody against oxidized low density lipoprotein. J. Biol. Chem. 271:1996;33208-33217.
37. Tatzber F, Esterbauer H. Autoantibodies to oxidized low density lipoprotein. Bellomo G, Finardi G, Maggi E, Rice-Evance C Free Radicals, Lipoprotein Oxidation and Atherosclerosis. 1995;245-262 Richelieu, London.
38. 2+/dextran sulfate in its enzymic measurement. Clin. Chem. 24:1978;931-933.
39. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18:1972;499-502.
40. Kotani K., Maekawa M., Kanno T. et al. Distribution of immunoreactive malonaldehyde-modified low density lipoprotein in human serum. Biochem. Biophys. Acta. 1215:1994;121-125.
41. Holvoet P., Stassen J.-M., van Cleemput V., Collen D., Vanhaecke J. Oxidized low density lipoproteins in patients with transplant-associated coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 18:1998;100-107.
42. Miyazaki A., Sakai M., Suginohara Y., Hakamata H., Sakamot Y., Morikawa W., Horiuchi S. Acetylated low density lipoprotein reduces its ligand activity for the scavenger receptor after interaction with reconstituted high density lipoprotein. J. Biol. Chem. 269:1994;5264-5269.
43. Suzuki H., Kurihara Y., Takeya M., Kamada N., Kataoka M., Jishage K., Ueda O., Sakaguchi H., Higashi T., Suzuki T. et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature. 386:1997;292-296.
44. Ling W.H., Lougheed M., Suzuki H., Buchan A., Kodama T., Steinbrecher U.P. Oxidized or acetylated low density lipoproteins are rapidly cleared by the liver in mice with disruption of the scavenger receptor class A type I/II gene. J. Clin. Invest. 100:1997;244-252.
45. Lopes-Virella M.F., Binzafar N., Rackley S., Takei A., La Via M., Virella G. The uptake of LDL-IC by human macrophages: predominant involvement of the FcγRI receptor. Atherosclerosis. 135:1997;161-170.
46. Morganelli P.M., Rogers R.A., Kitzmiller T.J., Bergereon A. Enhanced metabolism of LDL aggregates mediated by specific human monocyte IgG Fc receptors. J. Lipid Res. 36:1995;714-724.
47. Unkeless J. Function and heterogeneity of human Fc receptors for immunoglobulin G. J. Clin. Invest. 83:1989;355-361.
48. Wiklund O., Witztum J.L., Carew T.E., Pittman R.C., Elam R.L., Steinberg D. Turnover and tissue sites of degradation of glucosylated low density lipoprotein in normal and immunized rabbits. J. Lipid Res. 28:1987;1098-1109.
49. Mackness M.I., Mackness B., Durrington P.N., Connelly P.W., Hegele R.A. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr. Opin. Lipidol. 7:1996;69-76.
50. Navab M., Hama S.Y., Hough G.P., Hedrick C.C., Sorenson R., La Du B.N., Kobashigawa J.A., Fonarow G.C., Berliner J.A., Laks H., Fogelman A.M. High density associated enzymes: their role in vascular biology. Curr. Opin. Lipidol. 9:1998;449-456.
51. Klimov A.N., Denisenko A.D., Vinogradov A.G., Nagarnev V.A., Pivovarova Y.I., Sitnikova O.D., Pleskov V.M. Accumulation of CE in macrophages incubated with human lipoprotein-antibody autoimmune complex. Atherosclerosis. 74:1988;41-46.
52. Hulthe J., Wikstrand J., Lidell A., Wendelhag I., Hansson G.K., Wiklund O. Antibody titers against oxidized LDL are not elevated in patients with familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 18:1998;1203-1211.